Pages that link to "Q69918671"
Jump to navigation
Jump to search
The following pages link to Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience (Q69918671):
Displaying 50 items.
- Therapy-related myeloid leukemia (Q28284888) (← links)
- Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group. (Q30985931) (← links)
- T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report (Q33592181) (← links)
- Oral alkylating agents for breast cancer therapy (Q33859915) (← links)
- Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy (Q33928011) (← links)
- Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005 (Q33938533) (← links)
- Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. (Q33944747) (← links)
- Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. (Q34682963) (← links)
- The clinical impact of expert pathological review on lymphoma management: a regional experience (Q35583436) (← links)
- Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients (Q35597072) (← links)
- Incidence of acute myeloid leukemia after breast cancer (Q35640784) (← links)
- Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide (Q36028830) (← links)
- Late immune and haemopoietic functions in plasmacytoma-bearing mice cured by melphalan (Q36466102) (← links)
- Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review (Q36746777) (← links)
- Multiple primary cancers in Connecticut, 1935-82 (Q36989325) (← links)
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide follow (Q37118467) (← links)
- Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy (Q37457332) (← links)
- Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation (Q37903265) (← links)
- Current management of carcinoma of the breast (Q40684734) (← links)
- Clinical decision-making in early breast cancer (Q40852169) (← links)
- Influence of modifications in breast irradiation technique on dose outside the treatment volume (Q40898348) (← links)
- Comorbidity risk parameters associated with advanced breast cancer and systemic disease. Management of nonbreast disease. (Q40931732) (← links)
- Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment (Q41055089) (← links)
- Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation (Q41632376) (← links)
- Dose-dependent cytotoxic and mutagenic effects of antineoplastic alkylating agents on human lymphoblastoid cells (Q41700785) (← links)
- Second malignancies after breast cancer: The impact of adjuvant therapy (Q42332612) (← links)
- Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk (Q43764496) (← links)
- Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer (Q44117851) (← links)
- Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy (Q44574460) (← links)
- Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies (Q44577742) (← links)
- Use of the Seer Cancer Registry for Technology Assessment (Q45075125) (← links)
- Secondary haematological malignancies in the BCIRG 001 study. (Q46214254) (← links)
- The cancer burden in the United Kingdom in 2007 due to radiotherapy (Q51450646) (← links)
- Forty-year experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy. (Q53813775) (← links)
- Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation (Q61873065) (← links)
- Therapy-related acute nonlymphocytic leukemia: clinical aspects (Q67972894) (← links)
- Quantifying the carcinogenicity of antineoplastic drugs (Q68411815) (← links)
- Survival in acute non-lymphocytic leukaemia following breast cancer (Q68618736) (← links)
- Secondary leukaemia in lymphoma patients (Q69876340) (← links)
- Secondary leukaemia in Hodgkin's disease (Q69880684) (← links)
- Acute leukaemia following renal transplantation (Q71683457) (← links)
- Harvard report on cancer prevention. Causes of human cancer. Prescription drugs (Q71810848) (← links)
- Predicting recurrence in axillary-node negative breast cancer patients (Q72871989) (← links)
- Mitoxantrone-related acute myelocytic leukemias (Q73269088) (← links)
- Increased risk of second cancers following breast cancer: role of the initial treatment (Q74244606) (← links)
- Long-term results of neoadjuvant radiation therapy for breast cancer (Q74270101) (← links)
- Secondary leukemias induced by topoisomerase-targeted drugs (Q77333785) (← links)
- Increased incidence of tongue cancer after primary radiotherapy for nasopharyngeal carcinoma--the possibility of radiation carcinogenesis (Q78128596) (← links)
- Breast cancer and chronic myeloid leukemia: a short review (Q80485861) (← links)
- Leukemogenic effect of chemotherapy in patients with breast carcinoma: is it a real concern? (Q80587716) (← links)